Two of the biggest names in the state’s life sciences scene are joining forces. The collaboration between Eli Lilly and Co. (NYSE: LLY) and Roche Diagnostics Corp. in Indianapolis involves development of a method to test for Alzheimer’s disease.
The partnership involves a commercially-scalable tool to detect a key marker for the incurable condition.
Vice President of Lilly’s Alzheimer’s disease platform Phyllis Ferrell says "we are excited to partner with Roche Diagnostics on this important test. We share the same commitment to providing people with Alzheimer’s disease the best care possible, which includes detection as well as diagnosis and education."
As part of the non-exclusive deal, Lilly’s responsibilities include payments upon success of key development objectives and Roche handling development, registration and commercialization of the test.
Lilly says more than 7.4 million Americans are expected to be affected by the disease by 2025.